


PHARMACEUTICAL 2020



UNITED THERAPEUTICS Corp Rank 45 of 362





PHARMACEUTICAL 2020





UNITED THERAPEUTICS Corp Rank 45 of 362

The relative strengths and weaknesses of UNITED THERAPEUTICS Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of UNITED THERAPEUTICS Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 260% points. The greatest weakness of UNITED THERAPEUTICS Corp is the variable Research and Development, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 104%, being 407% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	1,864,500
Cost of Goods Sold	117,600
Intangible Assets	0
Liabilities, Current	463,000
Liabilities, Non-Current	70,000
Other Assets	1,310,400
Other Compr. Net Income	-6,300
Other Expenses	275,700
Other Liabilities	600,000
Other Net Income	22,600
Property and Equipment	738,500
Research and Development	1,182,600
Revenues	1,448,800
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	3,913,400
Liabilities	1,133,000
Expenses	1,575,900
Stockholders Equity	2,780,400
Net Income	-104,500
Comprehensive Net Income	-107,650
Economic Capital Ratio	104%